Thrombotic thrombocytopenic purpura (TTP) is diagnosed through a combination of blood tests, clinical scoring, and a definitive enzyme test. The key confirmatory finding is an ADAMTS13 activity level below 10%, but because TTP can be fatal within hours if untreated, doctors typically begin treatment based on earlier clues while waiting for that result.
Why Speed Matters in TTP Diagnosis
TTP is a blood disorder where tiny clots form throughout small blood vessels, consuming platelets and shredding red blood cells in the process. Without treatment, it can cause strokes, organ failure, and death. Expert guidelines recommend starting plasma exchange within 4 to 8 hours of a suspected diagnosis, even before confirmatory test results come back. When plasma exchange isn’t immediately available, large-volume plasma infusion is recommended as a bridge.
This urgency shapes the entire diagnostic approach. Doctors don’t wait for a single definitive test. Instead, they layer increasingly specific information: first routine blood work, then a clinical risk score, then the confirmatory enzyme test that arrives days later.
Initial Blood Work
The first signs of TTP show up on a standard complete blood count and a blood smear viewed under a microscope. Two findings raise immediate suspicion: a very low platelet count and evidence that red blood cells are being physically torn apart as they pass through clot-narrowed blood vessels.
The torn red blood cells, called schistocytes, appear as jagged fragments on a blood smear. Some experts consider schistocytes essential for the diagnosis, though they may not appear early in the illness. Other markers of red blood cell destruction include elevated indirect bilirubin (a breakdown product), undetectable haptoglobin (a protein that mops up free hemoglobin), and a high reticulocyte count (immature red blood cells the bone marrow releases to compensate for losses).
Critically, standard clotting tests like the PT and INR are typically normal in TTP. This helps separate it from other dangerous conditions that also cause low platelets and red blood cell damage.
The PLASMIC Score
Once initial blood work suggests TTP is possible, doctors use a scoring tool called the PLASMIC score to estimate the likelihood that the underlying enzyme, ADAMTS13, is severely deficient. The score has seven yes-or-no criteria, each worth one point:
- Platelet count below 30,000 (normal is 150,000 to 400,000)
- Signs of red blood cell destruction (reticulocyte count above 2.5%, undetectable haptoglobin, or indirect bilirubin above 2.0 mg/dL)
- No active cancer in the past year
- No history of organ or stem cell transplant
- Mean red blood cell size below 90 femtoliters
- INR below 1.5 (a normal clotting test)
- Creatinine below 2.0 mg/dL (relatively preserved kidney function)
A score of 0 to 4 means low risk for severe ADAMTS13 deficiency. A score of 5 is intermediate risk. A score of 6 or 7 is high risk, and these patients are typically treated for TTP immediately while awaiting the confirmatory enzyme test. Notice that the score also helps distinguish TTP from lookalike conditions: cancer, transplant complications, kidney failure, and clotting disorders all push the score lower and point toward other diagnoses.
The Confirmatory Test: ADAMTS13 Activity
ADAMTS13 is an enzyme that cuts a large, sticky blood protein called von Willebrand factor into smaller, less dangerous pieces. When ADAMTS13 is missing or blocked, ultra-large strands of von Willebrand factor accumulate and trap platelets, forming the widespread tiny clots that define TTP.
An ADAMTS13 activity level below 10% confirms the diagnosis. This test is considered definitive by the American Society of Hematology, though results often take two to three days at most hospitals because the assay is performed at specialized reference laboratories. That delay is precisely why the clinical scoring and early blood work matter so much for guiding treatment decisions in the interim.
Not every patient who fits the clinical picture of TTP will have ADAMTS13 levels below 10%. Some patients with moderately reduced levels still receive a TTP diagnosis based on the overall clinical and lab picture. But a level below 10% removes diagnostic uncertainty.
Immune TTP vs. Congenital TTP
Once severe ADAMTS13 deficiency is confirmed, the next question is why the enzyme is missing. This distinction changes long-term management significantly.
In immune TTP, the far more common form, the immune system produces antibodies that attack and neutralize ADAMTS13. Doctors detect these antibodies using two main methods. One is an ELISA test, which identifies both inhibitory antibodies (those that directly block the enzyme) and non-inhibitory antibodies (those that accelerate its clearance from the blood). The other is a Bethesda-style assay, similar to the test used for hemophilia inhibitors, which specifically measures how much a patient’s plasma can suppress ADAMTS13 function. If the ELISA is positive or the Bethesda assay shows inhibitory activity, the diagnosis is immune TTP.
Congenital TTP, sometimes called Upshaw-Schulman syndrome, results from inherited mutations in the ADAMTS13 gene. These patients have chronically low ADAMTS13 levels from birth but may not be diagnosed until a triggering event like pregnancy, infection, or surgery pushes them into a crisis. The absence of detectable antibodies in a patient with very low ADAMTS13 activity points toward the congenital form, which can be confirmed with genetic testing.
Ruling Out Conditions That Mimic TTP
Several other conditions cause low platelets and red blood cell fragmentation, so part of diagnosing TTP is ruling these out. The two most important mimics are hemolytic uremic syndrome (HUS) and disseminated intravascular coagulation (DIC).
HUS primarily damages the kidneys and is often triggered by a toxin-producing bacterial infection. Patients with HUS tend to have much higher creatinine levels and more severe kidney involvement than TTP patients. This is one reason the PLASMIC score includes a creatinine cutoff: a creatinine above 2.0 mg/dL makes TTP less likely and HUS more likely.
DIC is a widespread clotting and bleeding disorder usually triggered by severe infection, trauma, or cancer. Unlike TTP, DIC causes abnormal clotting tests. The PT and INR are elevated, and fibrinogen is often consumed. Research has also identified more precise ways to separate the two: patients with immune TTP have dramatically lower haptoglobin levels (median 0.39 mg/dL) compared to patients with septic DIC (median 54.20 mg/dL). A combined index using haptoglobin and a clotting factor called factor XIII activity distinguished the two conditions with 94% sensitivity and 87% specificity in one study.
Other conditions on the differential include severe preeclampsia and HELLP syndrome in pregnant patients, catastrophic antiphospholipid syndrome, and malignant hypertension. Each has distinguishing clinical features, but the ADAMTS13 activity test ultimately settles the question when TTP is suspected.
What the Diagnostic Timeline Looks Like
In practice, the diagnostic process unfolds in overlapping stages. A patient typically arrives at the emergency department with some combination of fatigue, bruising, confusion, or dark urine. Routine blood work comes back within an hour showing severely low platelets and fragmented red blood cells on the smear. The PLASMIC score is calculated at the bedside using those initial results.
If the score is high, treatment with plasma exchange begins within hours while an ADAMTS13 activity sample is sent to a reference lab. Antibody testing is usually sent at the same time. Over the following two to three days, the ADAMTS13 result returns and either confirms the diagnosis or redirects the clinical team toward an alternative explanation. If antibodies are detected, the diagnosis of immune TTP is established. If not, genetic testing for congenital TTP may follow.
This layered approach, acting on clinical probability before waiting for definitive confirmation, is what makes TTP diagnosis distinct from most other blood disorders. The stakes of a missed or delayed diagnosis are simply too high to wait.